Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

651824.pdf (185.22 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2015-04-15

Llicència de publicació

cc-by (c) González Ortega, Itxaso et al., 2015
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/103066

Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1371/journal.pone.0123707

Resum

BACKGROUND: Although depressive symptoms in first episode psychosis have been associated with cannabis abuse, their influence on the long-term functional course of FEP patients who abuse cannabis is unknown. The aims of the study were to examine the influence of subclinical depressive symptoms on the long-term outcome in first episode-psychosis patients who were cannabis users and to assess the influence of these subclinical depressive symptoms on the ability to quit cannabis use. METHODS: 64 FEP patients who were cannabis users at baseline were followed-up for 5 years. Two groups were defined: (a) patients with subclinical depressive symptoms at least once during follow-up (DPG), and (b) patients without subclinical depressive symptoms during follow-up (NDPG). Psychotic symptoms were measured using the Positive and Negative Syndrome Scale (PANSS), depressive symptoms using the Hamilton Depression Rating Scale (HDRS)-17, and psychosocial functioning was assessed using the Global Assessment of Functioning (GAF). A linear mixed-effects model was used to analyze the combined influence of cannabis use and subclinical depressive symptomatology on the clinical outcome. RESULTS: Subclinical depressive symptoms were associated with continued abuse of cannabis during follow-up (β= 4.45; 95% confidence interval [CI]: 1.78 to 11.17; P = .001) and with worse functioning (β = -5.50; 95% CI: -9.02 to -0.33; P = .009). CONCLUSIONS: Subclinical depressive symptoms and continued cannabis abuse during follow-up could be predictors of negative outcomes in FEP patients.

Matèries

Depressió psíquica, Cànnabis, Psicosi, Psicopatologia

Matèries (anglès)

Mental depression, Cannabis, Psychoses, Pathological psychology

Citació

Col·leccions

Articles publicats en revistes (Medicina)

Citació

GONZÁLEZ ORTEGA, Itxaso, et al. Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis. PLoS One. 2015. Vol. 10, num. 4, pags. e0123707. ISSN 1932-6203. [consulted: 3 of August of 2026]. Available at: https://hdl.handle.net/2445/103066

Exportar metadades

JSON - METS

Compartir registre